Published in Gene Therapy Weekly, August 18th, 2005
"Deregulated tumor growth and neovascularization result in an inadequate tumor blood supply, leading to areas of chronic hypoxia and necrosis. Irregular vascular structure and abnormal tumor physiology also cause erratic blood flow in tumor vessels," scientists in England report.
"We reasoned that tumor stroma, including vascular endothelial cells, would consequently experience transient hypoxia that may allow transcriptional targeting as part of an antivascular gene therapy approach to cancer," said N. Ingram and colleagues, Institute for Cancer Research.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.